MedTrace Logo

Kava Kava for the Treatment of Generalized Anxiety Disorder (GAD)

NCT00083980 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2012-10-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of the herbal medicine kava kava for the treatment of generalized anxiety disorder (GAD).

Conditions

  • Anxiety Disorders

Interventions

DRUG

Venlafaxine ER

75 to 225 mg daily

DRUG

Sugar pill

Upto 3 per day for venlafainxe and 4 per day for kava placebos.

DRUG

Kava

140 to 280 mg per day

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    lead NIH

Principal Investigators

  • Jonathan Davidson, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2004-06-30
Completion
2004-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00083980 on ClinicalTrials.gov